CSIMarket Company Name, Ticker, Competitors, else..
 
Radnet Inc   (RDNT)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $27.6100 $0.31 1.136%
Day's High: $27.805 Week Perf: -1.46 %
Day's Low: $ 27.02 30 Day Perf: -12.6 %
Volume (M): 324 52 Wk High: $ 35.18
Volume (M$): $ 8,932 52 Wk Avg: $24.98
Open: $27.31 52 Wk Low: $12.03



 Market Capitalization (Millions $) 1,682
 Shares Outstanding (Millions) 61
 Employees 8,700
 Revenues (TTM) (Millions $) 1,528
 Net Income (TTM) (Millions $) 12
 Cash Flow (TTM) (Millions $) 257
 Capital Exp. (TTM) (Millions $) 256

Radnet Inc
Radnet Inc is a leading provider of diagnostic imaging services, including MRI, CT, PET/CT, X-ray, ultrasound, and mammography. The company operates a network of outpatient radiology centers and provides radiology services to hospitals and healthcare providers nationwide.

Founded in 1985, Radnet has grown to become one of the largest providers of diagnostic imaging services in the United States. The company has over 300 imaging centers across 6 states, including California, Maryland, Delaware, New Jersey, New York, and Florida.

Radnet's services are provided by a team of board-certified radiologists, technologists, and support staff, who work together to provide the highest quality of care to their patients. The company is committed to using the latest technology and imaging techniques to ensure accurate and timely diagnoses.

In addition to its diagnostic imaging services, Radnet also provides a range of healthcare IT solutions, including radiology information systems and picture archiving and communication systems. These solutions enable healthcare providers to streamline their workflow and improve patient care.

Radnet is also committed to giving back to the communities it serves. The company sponsors various charity events and provides free imaging services to underserved populations.

Overall, Radnet is a leading provider of diagnostic imaging services, with a commitment to providing the highest quality of care to its patients through the use of the latest technology and imaging techniques.


   Company Address: 1510 Cotner Avenue Los Angeles, 90025 CA
   Company Phone Number: 478-7808   Stock Exchange / Ticker: NASDAQ RDNT
   RDNT is expected to report next financial results on November 08, 2023.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
      % 
• View Complete Report
   



Aclarion Inc

Aclarion Inc's Performance in Q2 2023 Raises Concerns Despite Impressive Revenue Growth



In this bearish article, we will examine Aclarion Inc's financial performance, primarily focusing on the financial time-frame closing on June 30, 2023, and its implications for the company's future. Despite an impressive revenue growth of 59.91%, there are underlying concerns that cannot be ignored. Additionally, recent trading activity and the stock's year-to-date performance indicate a declining trend. This article aims to highlight and explain these issues.
Financial Results and Revenue Growth:
Aclarion Inc showcased balanced books of $0.00 per share for the financial time-frame closing June 30, 2023. While this might initially seem positive from a profitability standpoint, it is vital to note that it remains unchanged both from the previous year and the prior reporting season. This stagnant performance raises concerns about Aclarion's ability to generate consistent profits.
Delwinds Insurance Acquisition Corp

Delwinds Insurance Acquisition Corp Reports Revenue of $0.012 Million in Q2 2023

Medical Laboratories Company Reports Modest Revenue in Q2 2023 Earnings Season
In the latest quarterly financial report released by the Medical Laboratories company, it has been revealed that the company generated revenue amounting to $0.012 million during the second quarter of the 2023 earnings season. While this figure may seem modest, it reflects the company's ongoing efforts to navigate the challenging market conditions currently impacting the healthcare industry.
Despite the relatively low revenue, Medical Laboratories remains focused on its core competencies and continues to deliver quality services to its clients. The company's strong reputation in the market has allowed it to maintain a steady stream of business, despite the headwinds it faces.
Invitae Corporation

Battling Strong Headwinds, Invitae Corporation Powers Through to Deliver Stellar Q2 2023 Earnings


Introduction
Invitae Corporation, a prominent player in the Medical Laboratories sector, reported disappointing financial results for the April to June 30 2023 time-frame. The company's earnings per share (EPS) declined to $-0.78, compared to $-10.87 a year earlier, representing a significant increase in losses. Furthermore, revenue plummeted by 11.777% to $120.53 million from $136.62 million in the prior year, while sequentially increasing by a meager 2.706% from $117.36 million.
Revenue Contrast
Contrasting with the growth observed in the remainder of the Medical Laboratories sector, which recorded a revenue increase of 3.98% in the second quarter of 2023 compared to the same reporting period a year ago, Invitae Corporation suffered a substantial decrease in revenue. This decline puts the company at a clear disadvantage within its industry, indicating a failure to adapt to current market trends and potential internal inefficiencies.
Bionexus Gene Lab Corp

Bionexus Gene Lab Corp Reports Modest Growth in Top-line Revenue during Fiscal Q2 2023



Bionexus Gene Lab Corp (BGLC) recently released its financial results for the second quarter of 2023. In order to understand the implications of these results and their potential effects on the company's future, it is crucial to delve deeper into the figures and analyze them in the context of the overall medical laboratories sector.
Revenue Growth and Comparison:
During the second quarter of 2023, BGLC's revenue witnessed a slight increase of 3.289% to reach $2.57 million. This should be seen in relation to the corresponding period a year earlier, when the company generated $2.49 million in revenue. Furthermore, Q2 2023 revenue also recorded a sequential growth of 7.978% from $2.38 million.
Biocept Inc

Biocept Inc's Second Quarter 2023 Report Reveals Shocking -94.449% Drop in Revenue: a Critical Concern for the Medical Laboratories Sector

Biocept Inc (BIOC) has recently released its second-quarter financial report for 2023, and the results are disastrous. The company's revenue plummeted by a staggering -94.449% to a mere $0.59 million. This significant decline in revenue is alarming, especially when compared to the rest of the Medical Laboratories sector, which experienced revenue growth during the same period.
Furthermore, the company's shortfall per share has widened to $-3.50, a considerable deterioration from the previous year's reporting season. In comparison to the prior reporting season, revenue deteriorated sequentially by -12.481% from $0.67 million.





 

Radnet Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com